Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis

被引:39
作者
Accortt, Neil A. [1 ]
Lesperance, Tamara [2 ]
Liu, Mei [3 ]
Rebello, Sabrina [3 ]
Trivedi, Mona [1 ]
Li, Youfu [4 ]
Curtis, Jeffrey R. [5 ]
机构
[1] Amgen Inc, One Amgen Ctr Dr,Mail Stop 24-2-A, Thousand Oaks, CA 91320 USA
[2] DOCS Global, N Wales, PA USA
[3] Corrona LLC, Southborough, MA USA
[4] Univ Massachusetts, Worcester, MA 01605 USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
关键词
DISEASE-ACTIVITY; MORTALITY; ETANERCEPT; ADALIMUMAB; INFLIXIMAB; THERAPY;
D O I
10.1002/acr.23426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. This retrospective analysis examined how sustained remission impacted risk of serious infections in patients with rheumatoid arthritis (RA) enrolled in a clinical registry. Methods. Inclusion criteria included RA diagnosis, age >= 18 years, and >= 2 Clinical Disease Activity Index (CDAI) scores followed by a followup visit. Index date was the second of 2 visits in which a patient had sustained remission (CDAI <= 2.8), low disease activity (LDA; 2.8 < CDAI <= 10), or moderate-to-high disease activity (MHDA; CDAI >10). Followup extended from the index date until first serious infection (requiring intravenous antibiotics or hospitalization) or last followup visit. The crude incidence rate (IR) per 100 patient-years for serious infections was calculated for the sustained remission, LDA, and MHDA groups. The multivariable-adjusted incidence rate ratio (IRR) (adjusted for age, sex, and prednisone dose) compared serious infection rates across disease activity groups. Results. Most patients were female (>70%); mean age was approximately 60 years. The crude IR (95% confidence interval [95% CI]) per 100 patient-years for serious infections was 1.03 (0.85-1.26) in the sustained remission group (n = 3,355), 1.92 (1.68-2.19) in the sustained LDA group (n = 3,912), and 2.51 (2.23-2.82) in the sustained MHDA group (n = 5,062). Compared to sustained remission, the serious infection rate was higher in sustained LDA (adjusted IRR 1.69 [95% CI 1.32-2.15]). Compared to sustained LDA, the serious infection rate was higher in sustained MHDA (adjusted IRR 1.30 [95% CI 1.09-1.56]). Conclusion. In this study, lower RA disease activity was associated with lower serious infection rates. This finding may motivate patients and health care providers to strive for remission rather than only LDA.
引用
收藏
页码:679 / 684
页数:6
相关论文
共 25 条
  • [1] Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
    Aletaha, D
    Nell, VP
    Stamm, T
    Uffmann, M
    Pflugbeil, S
    Machold, K
    Smolen, JS
    [J]. ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) : R796 - R806
  • [3] World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20): : 2191 - 2194
  • [4] Aschengrau A., 2003, ESSENTIALS EPIDEMIOL
  • [5] Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry
    Atzeni, Fabiola
    Sarzi-Puttini, Piercarlo
    Botsios, Costantino
    Carletto, Antonio
    Cipriani, Paola
    Favalli, Ennio Giulio
    Frati, Elena
    Foschi, Valentina
    Gasparini, Stefania
    Giardina, AnnaRita
    Gremese, Elisa
    Iannone, Florenzo
    Sebastiani, Marco
    Ziglioli, Tamara
    Biasi, Domenico
    Ferri, Clodoveo
    Galeazzi, Mauro
    Gerli, Roberto
    Giacomelli, Roberto
    Gorla, Roberto
    Govoni, Marcello
    Lapadula, Giovanni
    Marchesoni, Antonio
    Salaffi, Fausto
    Punzi, Leonardo
    Triolo, Giovanni
    Ferraccioli, Gianfranco
    [J]. AUTOIMMUNITY REVIEWS, 2012, 12 (02) : 225 - 229
  • [6] High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
    Au, Karen
    Reed, George
    Curtis, Jeffrey R.
    Kremer, Joel M.
    Greenberg, Jeffrey D.
    Strand, Vibeke
    Furst, Daniel E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (05) : 785 - 791
  • [7] Glucocorticoids in the treatment of early and late RA
    Bijlsma, JWJ
    Boers, M
    Saag, KG
    Furst, DE
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (11) : 1033 - 1037
  • [8] Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens:: current questions and tentative answers in rheumatology
    Buttgereit, F
    da Silva, JAP
    Boers, M
    Burmester, GR
    Cutolo, M
    Jacobs, J
    Kirwan, J
    Köhler, L
    van Riel, P
    Vischer, T
    Bijlsma, JWJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (08) : 718 - 722
  • [9] Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis
    Curtis, J. R.
    Yang, S.
    Patkar, N. M.
    Chen, L.
    Singh, J. A.
    Cannon, G. W.
    Mikuls, T. R.
    Delzell, E.
    Saag, K. G.
    Safford, M. M.
    Duvall, S.
    Alexander, K.
    Napalkov, P.
    Winthrop, Kevin L.
    Burton, M. J.
    Kamauu, A.
    Baddley, J. W.
    [J]. ARTHRITIS CARE & RESEARCH, 2014, 66 (07) : 990 - 997
  • [10] Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients
    Curtis, Jeffrey R.
    Xie, Fenglong
    Chen, Lang
    Muntner, Paul
    Grijalva, Carlos G.
    Spettell, Claire
    Fernandes, Joaquim
    Mcmahan, Raechele M.
    Baddley, John W.
    Saag, Kenneth G.
    Beukelman, Timothy
    Delzell, Elizabeth
    [J]. ARTHRITIS CARE & RESEARCH, 2012, 64 (10) : 1480 - 1489